Logo image of SCNI

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) Stock Overview

USA - NASDAQ:SCNI - US09073Q3039 - ADR

1.5 USD
+0.04 (+2.63%)
Last: 10/28/2025, 8:21:26 PM
1.42 USD
-0.08 (-5.33%)
After Hours: 10/28/2025, 8:21:26 PM

SCNI Key Statistics, Chart & Performance

Key Statistics
Market Cap4.73M
Revenue(TTM)658.00K
Net Income(TTM)4.80M
Shares3.15M
Float2.80M
52 Week High6.18
52 Week Low1.2
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)3.03
PE0.5
Fwd PEN/A
Earnings (Next)N/A N/A
IPO2007-06-07
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


SCNI short term performance overview.The bars show the price performance of SCNI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40

SCNI long term performance overview.The bars show the price performance of SCNI in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of SCNI is 1.5 USD. In the past month the price increased by 18.58%. In the past year, price decreased by -57.87%.

SCINAI IMMUNOTHERAPEUTICS LT / SCNI Daily stock chart

SCNI Latest News, Press Relases and Analysis

SCNI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.49 401.96B
AMGN AMGEN INC 13.39 157.25B
GILD GILEAD SCIENCES INC 15.23 146.27B
VRTX VERTEX PHARMACEUTICALS INC 24.93 108.30B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 62.38B
REGN REGENERON PHARMACEUTICALS 14.34 69.37B
ARGX ARGENX SE - ADR 90.81 51.50B
INSM INSMED INC N/A 34.94B
ONC BEONE MEDICINES LTD-ADR 5.11 34.80B
NTRA NATERA INC N/A 26.02B
BNTX BIONTECH SE-ADR N/A 25.25B
BIIB BIOGEN INC 9.31 21.86B

About SCNI

Company Profile

SCNI logo image Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.

Company Info

SCINAI IMMUNOTHERAPEUTICS LT

Jerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus

JERUSALEM IL

Employees: 31

SCNI Company Website

SCNI Investor Relations

Phone: 97289302529

SCINAI IMMUNOTHERAPEUTICS LT / SCNI FAQ

What does SCNI do?

Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.


What is the current price of SCNI stock?

The current stock price of SCNI is 1.5 USD. The price increased by 2.63% in the last trading session.


What is the dividend status of SCINAI IMMUNOTHERAPEUTICS LT?

SCNI does not pay a dividend.


What is the ChartMill technical and fundamental rating of SCNI stock?

SCNI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


Is SCINAI IMMUNOTHERAPEUTICS LT (SCNI) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on SCNI.


What is the market capitalization of SCNI stock?

SCINAI IMMUNOTHERAPEUTICS LT (SCNI) has a market capitalization of 4.73M USD. This makes SCNI a Nano Cap stock.


Can you provide the ownership details for SCNI stock?

You can find the ownership structure of SCINAI IMMUNOTHERAPEUTICS LT (SCNI) on the Ownership tab.


SCNI Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to SCNI. When comparing the yearly performance of all stocks, SCNI is a bad performer in the overall market: 92.63% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

SCNI Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to SCNI. SCNI may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SCNI Financial Highlights

Over the last trailing twelve months SCNI reported a non-GAAP Earnings per Share(EPS) of 3.03.


Industry RankSector Rank
PM (TTM) 728.88%
ROA 40.51%
ROE 61.03%
Debt/Equity 0.04
Chartmill High Growth Momentum
EPS Q2Q%36.36%
Sales Q2Q%172.18%
EPS 1Y (TTM)N/A
Revenue 1Y (TTM)N/A

SCNI Forecast & Estimates


Analysts
Analysts82.86
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

SCNI Ownership

Ownership
Inst Owners7.84%
Ins Owners2.37%
Short Float %1.22%
Short Ratio0.26